Designing tests that predict your risk of developing cancer.

STRATICYTETM – A digitally delivered oral cancer predictor.

Better Testing, Better Guidance, Better Outcomes

Proteocyte is revolutionizing cancer risk prediction with advanced biomarker analysis and digital pathology. Our flagship product, STRATICYTE, empowers healthcare professionals to identify oral cancer risks early, enabling personalized treatment plans and improved patient outcomes. Since 2011, we’ve been committed to delivering innovative solutions that transform cancer care and prevention.

Clinicians

Get started

Patients

Start your journey

Award-winning clinical and scientific quality

Medhealth Outlook Award.

Recent Blogs

Dr. Ken Pritzker’s Legacy and the Straticyte™ Revolution in Oral Cancer Diagnostics

Dr. Ken Pritzker, a globally respected pathologist, made significant strides in medical innovation as the Chief of Pathology at Toronto’s Mount Sinai Hospital from 1986 to 2008. With a career rich in leadership, over 290 scientific publications, and expertise spanning...

Improving Oral Cancer Risk Assessment: Comparing Traditional Grading Systems with S100A7 Biomarker Analysis

Oral cancer is a serious health problem that can be difficult to detect early. One challenge is accurately assessing the risk of precancerous oral lesions turning into cancer. Currently, doctors rely on a subjective grading system that can vary between different...

Press Releases

StrataDx & Proteocyte AI Announce Partnership Agreement serving U.S. markets

Toronto, ON; December 13, 2024 – Proteocyte AI—an innovative company that develops and commercializes individualized tests to predict risk of developing cancer, and StrataDx—a clinical and anatomic pathology diagnostic laboratory, announce a new strategic partnership...

Proteocyte Expands Globally with Distribution Agreement in Turkey

Toronto, ON; December 12, 2024 – Proteocyte Diagnostics announces its partnership with Pharmackt (www.pharmackt.com) to introduce their Oral Cancer Stratification Test, Straticyte, in Turkey for the first time. Pharmackt represents numerous pioneering Molecular...

United Healthcare Now Reimbursing Straticyte™ Test

Patients now have access to a ground-breaking Advanced Diagnostic Laboratory cancer predictive Test for patients at risk of oral cancer. Dallas, TX; October 28, 2024 – Proteocyte announced today that United Healthcare (UHC) is providing coverage for Straticyte™ for...

Proteocyte Announces Lawrence Murphy as Strategic Advisor Business Development

Toronto, ON; August 5, 2024 – Proteocyte is pleased to announce the appointment of Lawrence Murphy to the role of Strategic Advisor Business Development for both the U.S. and International markets, effective August 1, 2024. As a Senior Executive in the Laboratory...

Proteocyte AI named a Top 10 AI Healthcare Solution Providers of 2024

“With STRATICYTE leading the way, Proteocyte AI is poised to make a profound impact on oral cancer management, providing hope and healing to patients and healthcare professionals around the world.” We are excited to announce that Proteocyte AI is one of the Top 10 AI...

Proteocyte Announces Joseph Geraci, Ph.D. as Strategic Advisor, A.I.

Toronto, ON; June 12, 2024 - Proteocyte is pleased to announce the appointment of Joseph Geraci, Ph.D. to the new role of Strategic Advisor, A.I., effective June 3, 2024. Dr. Geraci has a very strong academic and research background which includes a Master of Science...

Proteocyte Announces Mark Rood as Key Accounts Director, U.S.

Toronto, ON; June 7, 2024 - Proteocyte is pleased to announce the appointment of Mark Rood as their Director of Key Accounts, USA. Mr. Rood brings over 15 years of experience in the U.S. surgical device industry including the dental surgery market with companies like...

Proteocyte Announces Dr. Paras B. Patel as new U.S. Lab Director

Toronto, ON; April 23, 2024 - Proteocyte AI is pleased to announce the opening of their U.S. lab operations in Dallas, Texas, and the appointment of Dr. Paras B. Patel as their U.S. Lab Director. Dr. Patel's breadth of training and experience has shaped his approach...

Proteocyte and the American Academy of Oral Medicine Announce Multi-Year Corporate Affiliate Program Agreement

Toronto, ON; January 2, 2024 - Proteocyte AI is pleased to announce a new 2-year Corporate Affiliate Program agreement with the American Academy of Oral Medicine (AAOM). This corporate affiliate program agreement further reinforces Proteocyte’s dedication to producing...

Proteocyte Welcomes Key Advisor Mark Smithyes as Strategic Advisor

Toronto, ON; November 3, 2023 - Proteocyte AI is pleased to announce that Mark Smithyes has joined the organization as a strategic advisor. Mark will play a key role in helping Proteocyte to raise additional capital as the company approaches several key milestones for...

Our Partners

The American Academy of Oral Medicine Support for People with Oral and Head and Neck Cancer Center for Oral Pathology Dallas Propath Minnesota Oral & Facial Surgery Southern California Orofacial Academy Freilich Oral and Maxillofacial Surgery StrataDx The American Academy of Oral Medicine Support for People with Oral and Head and Neck Cancer Center for Oral Pathology Dallas Propath Minnesota Oral & Facial Surgery Southern California Orofacial Academy Freilich Oral and Maxillofacial Surgery StrataDx The American Academy of Oral Medicine Support for People with Oral and Head and Neck Cancer Center for Oral Pathology Dallas Propath Minnesota Oral & Facial Surgery Southern California Orofacial Academy Freilich Oral and Maxillofacial Surgery StrataDx The American Academy of Oral Medicine Support for People with Oral and Head and Neck Cancer Center for Oral Pathology Dallas Propath Minnesota Oral & Facial Surgery Southern California Orofacial Academy Freilich Oral and Maxillofacial Surgery StrataDx

Easily manage the patient’s test order from start to finish.